• Alfresa Holdings made an additional equity investment in ReeNT in June 2026 under a new capital and business alliance agreement.
• The alliance targets commercialization in Japan of ReeNT's autologous nasal mucosal epithelial cell sheets for regenerative medicine.
• A May 2026 share buyback totaled JPY 15 billion, aimed at improving capital efficiency and shareholder returns.
• Also in May 2026, the group signed an agreement to acquire all shares of Nagashima Medical Instruments from Nagashima Holdings.
• The acquisition aims to strengthen medical-device development and manufacturing capabilities while expanding the group's product lineup.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alfresa Holdings Corporation published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.